- Category: Experimental HCV Drugs
- Published on Wednesday, 15 July 2015 00:00
- Written by HIVandHepatitis.com
The U.S. Food and Drug Administration has approved 2 new treatments for hepatitis C virus (HCV) genotypes 3 and 4, which account for millions of cases worldwide. Daclatasvir (Daklinza) received the nod for use in combination with sofosbuvir (Sovaldi) for hard-to-treat genotype 3, while AbbVie received approval for its 2D paritaprevir/ritonavir/ombitasvir coformulation for genotype 4. Options remain limited, however, for people with liver cirrhosis.